ArticleClinical rheumatology2014
Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.
Article in Clinical rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Lipid Metabolism Profiles in Rheumatic Diseases.Frontiers in pharmacology · 2021Review
- Lipid profile among girls with systemic lupus erythematosus.Rheumatology international · 2017Article
- Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.Frontiers in immunology · 2017Article
- ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.Laboratory investigation; a journal of technical methods and pathology · 2016Review
- IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study.Arthritis research & therapy · 2015Observational
- Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study was to evaluate anti-apolipoprotein A-I (Apo A-I) and carotid intima-media thickness (cIMT) as cardiovascular risk factors in Egyptian women with systemic lupus erythematosus (SLE). The study included 160 subjects, 80 women with SLE and 80 healthy women as a control group. Disease activity score (SLEDAI), disease damage index (SLICC/ACR), lipid profile, complement C3 and C4, high-sensitivity CRP (hsCRP), anti-dsDNA and anticardiolipin antibodies were evaluated in addition to anti-Apo A-I antibodies and cIMT. The mean age of patients was 28.35 ± 7.06 years with mean disease duration of 4.58 ± 3.36 years. Anti-Apo A-I antibody titer was significantly higher in SLE patients than in controls (mean 35.3 ± 6.8 vs. 21.4 ± 5.91 U/L; P = 0.000). Carotid ultrasound showed significantly thickened intima in SLE patients compared with control subjects (mean thickness, 0.5 ± 0.08 vs. 0.45 ± 0.06 mm; P = 0.003). Correlation studies with other cardiovascular risk factors demonstrated significant associations between anti-Apo A-I and SLEDAI, SLICC/ACR, C3 and C4. On the other hand, cIMT showed significant association with age, systolic blood pressure, hsCRP and body mass index. Thus, SLE disease activity is associated with a significant increase in anti-Apo A-I titer. Also, increased cIMT might be a cardiovascular risk factor in Egyptian patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.